Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
25 Marzo 2024 - 6:00AM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced the appointment of Mike Kelliher to the position of
Executive Vice President, Corporate Development and Strategy. Mr.
Kelliher, an accomplished leader with more than 20 years of
experience in the biopharmaceutical industry, brings to Ardelyx an
extensive array of mergers and acquisitions, business development,
strategy, finance and operational leadership expertise from leading
biotechnology and global pharmaceutical companies.
“This newly created position reflects the important inflection
point at which we at Ardelyx find ourselves: Envisioning and
building our future following the successful launch of two
first-in-class medicines within the past two years,” said Mike
Raab, president and chief executive officer of Ardelyx. “It is a
pleasure to welcome Mike at this critical period of our growth. His
experience and expertise defining and advancing corporate
strategies along with his proven track record of delivering
value-accretive collaborations and transactions strengthen our
leadership team and position us for success. We are excited to
welcome Mike to Team Ardelyx.”
“Ardelyx is a values-driven organization with a clear focus on
the patient, established following the launch of two products, both
of which provide a new option for patients who continued to have
unmet treatment needs,” said Mr. Kelliher. “I am excited to join
Ardelyx at this time as we explore all of the opportunities that
the company has to advance in its next phase of growth. The company
is well resourced, has a strong team at all levels of the
organization and is establishing itself as a disruptor in the
development and commercialization of innovative medicines. I look
forward to being a part of this exciting evolution and contributing
to the company's success.”
Most recently, Mr. Kelliher served as Group Vice President,
M&A and Business Development, at Horizon Therapeutics, a global
biotechnology company focused on researching, developing and
commercializing medicines for rare, autoimmune and severe
inflammatory diseases. Mr. Kelliher joined Horizon in 2014 and held
roles of increasing responsibility on the team that led an
aggressive growth and expansion agenda through acquisitions,
development collaborations and other transactions, including the
acquisition of Horizon by Amgen. He was instrumental in
transforming Horizon into a $28 billion innovation-driven biotech
company.
Prior to his time at Horizon, from 2009 to 2014, Mr. Kelliher
held financial roles at Elan Corporation (now Perrigo Company), a
leading global pharmaceutical company where he oversaw strategic
partnerships and collaborations and advised its Board of Directors
and senior leadership on investments, business development, product
commercialization and asset monetization. Mr. Kelliher began his
career in banking, public accounting and corporate finance and
holds a Bachelor of Commerce degree from the University College
Cork (Ireland). He is also an Associated Chartered Accountant.
About ArdelyxArdelyx was founded with a mission
to discover, develop and commercialize innovative, first-in-class
medicines that meet significant unmet medical needs. Ardelyx has
two commercial products approved in the United States, IBSRELA®
(tenapanor) and XPHOZAH® (tenapanor) as well as early-stage
pipeline candidates. Ardelyx has agreements for the development and
commercialization of tenapanor outside of the U.S. Kyowa Kirin
commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in
Japan. A New Drug Application for tenapanor for hyperphosphatemia
has been submitted in China with Fosun Pharma. Knight Therapeutics
commercializes IBSRELA in Canada. For more information, please
visit https://ardelyx.com/ and connect with us on X (formerly known
as Twitter), LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ardelyx (NASDAQ:ARDX)
Gráfica de Acción Histórica
De May 2023 a May 2024